Keri L Calkins1,2, Geetanjali Chander3,4, Corinne E Joshu3, Kala Visvanathan3,5, Anthony T Fojo3,4, Catherine R Lesko3, Richard D Moore3,4, Bryan Lau3,4. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. kcalkins@mathematica-mpr.com. 2. , Mathematica, Ann Arbor, MI, USA. kcalkins@mathematica-mpr.com. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Medical Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Abstract
PURPOSE: A comparison of stage at cancer diagnosis and cancer treatment rates between people with HIV (PWH) and the general US population is needed to identify any disparities by HIV status. METHODS: We compared 236 PWH in clinical care diagnosed with cancer from 1997 to 2014 to a sample from NCI's Surveillance, Epidemiology and End Results (SEER) Program, presumed to be HIV negative. We performed G-computation using random forest methods to estimate stage and treatment percent differences (PD) by HIV. We conducted sensitivity analyses among non-AIDS-defining cancers (NADC), by sex and by CD4 ≤ 200 or > 200 cells/mm3. RESULTS: PWH were less likely to be diagnosed at localized stage (PD = - 16%; 95% CI - 21, - 11) and more likely to be diagnosed at regional stage (PD = 14%; 95% CI 8, 19) than those in SEER. Cancer treatment rates were 13% lower among PWH as compared to SEER (95% CI - 18, - 8). The difference in percent receiving cancer treatment was more pronounced for those with lower CD4 at cancer diagnosis (PD -15%; 95% CI - 27, - 6). Lower treatment rates were observed among NADC, males, and women with CD4 ≤ 200. CONCLUSION: Cancer care for PWH could be improved by diagnosis at earlier stages and increasing rates of cancer treatment.
PURPOSE: A comparison of stage at cancer diagnosis and cancer treatment rates between people with HIV (PWH) and the general US population is needed to identify any disparities by HIV status. METHODS: We compared 236 PWH in clinical care diagnosed with cancer from 1997 to 2014 to a sample from NCI's Surveillance, Epidemiology and End Results (SEER) Program, presumed to be HIV negative. We performed G-computation using random forest methods to estimate stage and treatment percent differences (PD) by HIV. We conducted sensitivity analyses among non-AIDS-defining cancers (NADC), by sex and by CD4 ≤ 200 or > 200 cells/mm3. RESULTS:PWH were less likely to be diagnosed at localized stage (PD = - 16%; 95% CI - 21, - 11) and more likely to be diagnosed at regional stage (PD = 14%; 95% CI 8, 19) than those in SEER. Cancer treatment rates were 13% lower among PWH as compared to SEER (95% CI - 18, - 8). The difference in percent receiving cancer treatment was more pronounced for those with lower CD4 at cancer diagnosis (PD -15%; 95% CI - 27, - 6). Lower treatment rates were observed among NADC, males, and women with CD4 ≤ 200. CONCLUSION:Cancer care for PWH could be improved by diagnosis at earlier stages and increasing rates of cancer treatment.
Entities:
Keywords:
CD4; Cancer; Cancer stage; Cancer treatment; HIV infection
Authors: Nadia Howlader; Meredith S Shiels; Angela B Mariotto; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-07-14 Impact factor: 4.254
Authors: Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Julia L Marcus; Chun Chao; Wendy A Leyden; Lanfang Xu; Jeanette Yu; Michael A Horberg; Daniel Klein; William J Towner; Charles P Quesenberry; Donald I Abrams; Michael J Silverberg Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-02-24 Impact factor: 4.254
Authors: Meredith S Shiels; Erik H Koritzinsky; Christina A Clarke; Gita Suneja; Lindsay M Morton; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-12-10 Impact factor: 4.254
Authors: Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels Journal: Cancer Date: 2019-05-03 Impact factor: 6.860
Authors: Gita Suneja; Meredith S Shiels; Sharon K Melville; Melanie A Williams; Ramesh Rengan; Eric A Engels Journal: AIDS Date: 2013-01-28 Impact factor: 4.177
Authors: Pragna Patel; Carl Armon; Joan S Chmiel; John T Brooks; Kate Buchacz; Kathy Wood; Richard M Novak Journal: Open Forum Infect Dis Date: 2014-05-27 Impact factor: 3.835
Authors: Marie Helleberg; Margaret T May; Suzanne M Ingle; Francois Dabis; Peter Reiss; Gerd Fätkenheuer; Dominique Costagliola; Antonella d'Arminio; Matthias Cavassini; Colette Smith; Amy C Justice; John Gill; Jonathan A C Sterne; Niels Obel Journal: AIDS Date: 2015-01-14 Impact factor: 4.177